Ironwood Pharmaceuticals (IRWD) Non Operating Investment Income (2015 - 2023)

Ironwood Pharmaceuticals has disclosed Non Operating Investment Income across 9 years of filings, most recently posting $19000.0 for Q1 2023.

• Non Operating Investment Income for Q1 2023 came in at $19000.0, down 97.4% year-over-year; the trailing twelve-month figure through Dec 2023 was $19000.0 (down 89.56% YoY), and the FY2023 annual result was $19000.0, down 89.56% from the prior year.
• Non Operating Investment Income came in at $19000.0 for Q1 2023 at Ironwood Pharmaceuticals, up from -$18000.0 in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $4.5 million in Q4 2019 to a low of -$4.8 million in Q3 2019.
• The 5-year median for Non Operating Investment Income is -$18000.0 (2022), against an average of -$240176.5.
• Across the five-year window, Non Operating Investment Income surged 199.7% in 2019 and slumped 710.95% in 2021, its largest moves.
• Ironwood Pharmaceuticals' Non Operating Investment Income stood at $4.5 million in 2019, then slumped by 90.7% to $420000.0 in 2020, then plunged by 710.95% to -$2.6 million in 2021, then jumped by 99.3% to -$18000.0 in 2022, then jumped by 205.56% to $19000.0 in 2023.
• The last three Non Operating Investment Income figures came in at $19000.0 (Q1 2023), -$18000.0 (Q4 2022), and $151000.0 (Q3 2022), per Business Quant data.